Dresden [Germany], August 14 : As a result of the researchers' discovery of three proteins required for the virus to carry out its invasion, they have created compounds (possible medications) that can target one of the proteins, possibly opening the door to brand-new AIDS treatments.
“We have revealed a protein pathway that appears to have a direct impact on diseases, which opens up a new area for potential drug development,” says the study’s senior author Aurelio Lorico, MD PhD, Professor of Pathology and interim Chief Research Officer at Touro University Nevada College of Osteopathic Medicine.
In order for the viral components to be integrated into the DNA of the healthy cell during HIV infection, the virus must enter the cell and obtain access to the well guarded nucleus. But it's unclear how the viruses get past the barrier, and this is a hotly contested topic.
The newly identified pathway begins with HIV entering a cell wrapped inside a membrane package, called an endosome. The virus-containing endosome then pushes the protective nuclear membrane inward, forming an indentation known as a nuclear invagination. The endosome then moves inside the invagination to its inner tip, where the virus then slips into the nucleus.
The study found that three proteins were critical to the invasion: One protein (Rab7) is located on the membrane of the endosome, the second (VAP-A) is on the nuclear membrane where the invagination occurs, and the third (ORP3) connects the first two proteins together. An interaction among the three proteins is needed for the invasion to be successful, so targeting any of these proteins could halt the infection. The team has synthesized and tested molecules that interrupt the interaction among the proteins. The researchers observed that, in the presence of these molecules, HIV replication does not occur.
This pathway for nuclear access was first discovered in the team’s research on cancer metastasis and is likely involved in other diseases as well.
“This is an entirely new pathway and we have developed molecules (drugs) that block it,” says Lorico. “Although our research is at a pre-clinical stage, it is likely that the new drugs synthesized may have therapeutic activity in AIDS, other viral diseases, and possibly metastatic cancer and other diseases where nuclear transport is involved.” The team is currently looking at the pathway’s role in Alzheimer’s disease and metastasis of many types of cancer.
“Because the pathway we found may apply to many types of disease, there is a tremendous amount of work that needs to be done to understand the full benefits of this research,” says Dr. Denis Corbeil, co-leading author of the study, research group leader at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany.
“The ground-breaking research of Dr. Lorico and his team is a testimony to the importance that Touro University gives to its mission of service to humanity. The potential therapeutic applications of this new pathway to improve patient care are immense and may help us better navigate the next pandemic,” said Dr. Alan Kadish, Touro University President.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor